Pleiotropic Effects of ARB on Dyslipidemia

Author(s): Isao Taguchi, Teruo Inoue, Migaku Kikuchi, Shigeru Toyoda, Takuo Arikawa, Shichiro Abe, Koichi Node.

Journal Name: Current Vascular Pharmacology

Volume 9 , Issue 2 , 2011

Become EABM
Become Reviewer

Abstract:

Angiotensin II type 1 (AT1) receptor blockers (ARBs), widely used in the treatment of hypertension, have cardiovascular, cerebral, and renal protective effects beyond blood pressure control. In addition to direct end-organ protection, some ARBs have been suggested to improve abnormalities of glucose and lipid metabolisms, resulting in an antiatherosclerotic effect in patients with hypertension. In several clinical trials, the effects of ARBs on lipid metabolism have been emerged, although the effects are heterogeneous. Certain subgroups of ARBs such as telmisartan have been identified as partial agonists for the peroxisome proliferators activated receptor (PPAR)-γ, and thus, this class of ARBs has been mostly focused on their effects on lipid metabolism. Based on the pleiotropic effects on lipid metabolism, we can envision that ARBs would provide the promising outcome for hypertensive patients aggregating metabolic risk factors, including dyslipidemia.

Keywords: ARB, dyslipidemia, lipid metabolism, PPAR-γ

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 9
ISSUE: 2
Year: 2011
Page: [129 - 135]
Pages: 7
DOI: 10.2174/157016111794519336
Price: $58

Article Metrics

PDF: 3